Connect with us

Hi, what are you looking for?

Economy

Pfizer to get green light for emergency use application soon

THE PHILIPPINES is expected to grant the emergency use authorization for the coronavirus vaccine developed by Pfizer, according to the chief of the local Food and Drug Administration (FDA).

The vaccine made by the US drugmaker and its German partner BioNTech SE may get the green light by Jan. 14, FDA Director-General FDA Rolando Enrique D. Domingo told an online news briefing on Wednesday.

The review had been expedited because Pfizer has obtained emergency use listing from the World Health Organization (WHO) and authorization from several countries including the US, United Kingdom, Switzerland and Singapore, he said.

“The process is fast but we are going through each step to ensure the quality, safety and efficacy of the vaccines before we give approval,” Mr. Domingo said.

Results from a late-stage vaccine trial showed that the Pfizer vaccine is 95% effective after two shots.

AstraZeneca Plc has also applied for emergency use authorization of its COVID-19 vaccine in the Philippines, Mr. Domingo.

He said the British drugmaker has a tripartite supply deal with the private sector and Philippine government. It is in talks with local governments seeking to order vaccines, he added.

“The vaccine from Oxford and AstraZeneca was already approved in the United Kingdom and India,” Mr. Domingo said. “We anticipate that they will also apply in the Philippines.”

AstraZeneca’s vaccine, which was found to be 70% effective on average after two shots, is reportedly cheaper than the Pfizer/BioNTech vaccine and does not require super cold temperatures.

Mr. Domingo said the Pfizer vaccine, “the most in-demand brand,” would most likely become available locally in the third or fourth quarter.

Meanwhile, biotechnology companies in the Philippines will seek approval for emergency use authorization for a coronavirus vaccine made by Bharat Biotech India this month, IP Biotech, Inc. said in a statement.

The FDA will get the application from IP-Biotech, Family Vaccine & Specialty Clinics and Ambica International Corp., IP Biotech said after India’s drug regulator approved the vaccine.

Bharat Biotech India’s Covaxin was developed with the Indian Council of Medical Research-National Institute of Virology.

“The indigenous, inactivated, whole virus vaccine has a standard cold chain temperature of 2-8 degrees Celsius, making it ideal for tropical countries,” IP Biotech said in the statement. — Kyle Aristophere T. Atienza

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

A Saudi flag flutters atop Saudi Arabia’s consulate in Istanbul, Turkey Oct. 20, 2018. — REUTERS/HUSEYIN ALDEMIR/FILE PHOTO RIYADH — Saudi Arabia’s crown prince...

Economy

IN FEB. 2019, Facebook, Inc. set up a test account in India to determine how its own algorithms affect what people see in one...

Economy

CHINA’S economy risks slowing faster than investors realize as President Xi Jinping’s push to cut its reliance on real estate and regulate sectors from...

Economy

Faced with a high level of competition in an era of streaming services, content providers must stay ahead by developing a strong user experience...

Economy

The Philippines remains under a “gray” list of countries under increased monitoring for money laundering and terrorism financing risks, despite some progress in implementing...

Investing

A Brewdog promotion which said customers could win “solid gold” beer cans was misleading, the advertising watchdog has found. The Scottish brewer offered shoppers...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Economy

Pfizer Inc on Wednesday raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion, and said it believes people will...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.



Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!